Global Cancer Companion Diagnostic Market 2023 by Company, Regions, Type and Application, Forecast to 2029
According to our (Global Info Research) latest study, the global Cancer Companion Diagnostic market size was valued at USD million in 2022 and is forecast to a readjusted size of USD million by 2029 with a CAGR of % during review period.
Companion diagnostic (CD) is an in vitro diagnostic technology that can provide information about a patient's therapeutic response to a specific therapeutic drug, helping to identify patient groups who can benefit from a certain therapeutic product, thereby improving treatment prognosis. and reduce health care costs. Additionally, companion diagnostics can help identify patient populations most likely to respond to therapeutic agents. The companion diagnostics market is still in its early stages.
The number of cancer patients is gradually increasing, drug accessibility is improving, and the research and development of targeted drugs and immunotherapy continue to increase. This is the main trend of drug development in the next ten years.
The Global Info Research report includes an overview of the development of the Cancer Companion Diagnostic industry chain, the market status of Lung Cancer (Polymerase Chain Reaction (PCR), “Next Generation” Sequencing (NGS)), Colorectal Cancer (Polymerase Chain Reaction (PCR), “Next Generation” Sequencing (NGS)), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Cancer Companion Diagnostic.
Regionally, the report analyzes the Cancer Companion Diagnostic markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Cancer Companion Diagnostic market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Cancer Companion Diagnostic market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Cancer Companion Diagnostic industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Polymerase Chain Reaction (PCR), “Next Generation” Sequencing (NGS)).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Cancer Companion Diagnostic market.
Regional Analysis: The report involves examining the Cancer Companion Diagnostic market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Cancer Companion Diagnostic market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Cancer Companion Diagnostic:
Company Analysis: Report covers individual Cancer Companion Diagnostic players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Cancer Companion Diagnostic This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Lung Cancer, Colorectal Cancer).
Technology Analysis: Report covers specific technologies relevant to Cancer Companion Diagnostic. It assesses the current state, advancements, and potential future developments in Cancer Companion Diagnostic areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Cancer Companion Diagnostic market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Cancer Companion Diagnostic market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
Chapter 1, to describe Cancer Companion Diagnostic product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Cancer Companion Diagnostic, with revenue, gross margin and global market share of Cancer Companion Diagnostic from 2018 to 2023.
Chapter 3, the Cancer Companion Diagnostic competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Cancer Companion Diagnostic market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Cancer Companion Diagnostic.
Chapter 13, to describe Cancer Companion Diagnostic research findings and conclusion.
Companion diagnostic (CD) is an in vitro diagnostic technology that can provide information about a patient's therapeutic response to a specific therapeutic drug, helping to identify patient groups who can benefit from a certain therapeutic product, thereby improving treatment prognosis. and reduce health care costs. Additionally, companion diagnostics can help identify patient populations most likely to respond to therapeutic agents. The companion diagnostics market is still in its early stages.
The number of cancer patients is gradually increasing, drug accessibility is improving, and the research and development of targeted drugs and immunotherapy continue to increase. This is the main trend of drug development in the next ten years.
The Global Info Research report includes an overview of the development of the Cancer Companion Diagnostic industry chain, the market status of Lung Cancer (Polymerase Chain Reaction (PCR), “Next Generation” Sequencing (NGS)), Colorectal Cancer (Polymerase Chain Reaction (PCR), “Next Generation” Sequencing (NGS)), and key enterprises in developed and developing market, and analysed the cutting-edge technology, patent, hot applications and market trends of Cancer Companion Diagnostic.
Regionally, the report analyzes the Cancer Companion Diagnostic markets in key regions. North America and Europe are experiencing steady growth, driven by government initiatives and increasing consumer awareness. Asia-Pacific, particularly China, leads the global Cancer Companion Diagnostic market, with robust domestic demand, supportive policies, and a strong manufacturing base.
Key Features:
The report presents comprehensive understanding of the Cancer Companion Diagnostic market. It provides a holistic view of the industry, as well as detailed insights into individual components and stakeholders. The report analysis market dynamics, trends, challenges, and opportunities within the Cancer Companion Diagnostic industry.
The report involves analyzing the market at a macro level:
Market Sizing and Segmentation: Report collect data on the overall market size, including the revenue generated, and market share of different by Type (e.g., Polymerase Chain Reaction (PCR), “Next Generation” Sequencing (NGS)).
Industry Analysis: Report analyse the broader industry trends, such as government policies and regulations, technological advancements, consumer preferences, and market dynamics. This analysis helps in understanding the key drivers and challenges influencing the Cancer Companion Diagnostic market.
Regional Analysis: The report involves examining the Cancer Companion Diagnostic market at a regional or national level. Report analyses regional factors such as government incentives, infrastructure development, economic conditions, and consumer behaviour to identify variations and opportunities within different markets.
Market Projections: Report covers the gathered data and analysis to make future projections and forecasts for the Cancer Companion Diagnostic market. This may include estimating market growth rates, predicting market demand, and identifying emerging trends.
The report also involves a more granular approach to Cancer Companion Diagnostic:
Company Analysis: Report covers individual Cancer Companion Diagnostic players, suppliers, and other relevant industry players. This analysis includes studying their financial performance, market positioning, product portfolios, partnerships, and strategies.
Consumer Analysis: Report covers data on consumer behaviour, preferences, and attitudes towards Cancer Companion Diagnostic This may involve surveys, interviews, and analysis of consumer reviews and feedback from different by Application (Lung Cancer, Colorectal Cancer).
Technology Analysis: Report covers specific technologies relevant to Cancer Companion Diagnostic. It assesses the current state, advancements, and potential future developments in Cancer Companion Diagnostic areas.
Competitive Landscape: By analyzing individual companies, suppliers, and consumers, the report present insights into the competitive landscape of the Cancer Companion Diagnostic market. This analysis helps understand market share, competitive advantages, and potential areas for differentiation among industry players.
Market Validation: The report involves validating findings and projections through primary research, such as surveys, interviews, and focus groups.
Market Segmentation
Cancer Companion Diagnostic market is split by Type and by Application. For the period 2018-2029, the growth among segments provides accurate calculations and forecasts for consumption value by Type, and by Application in terms of value.
Market segment by Type
- Polymerase Chain Reaction (PCR)
- “Next Generation” Sequencing (NGS)
- Fluorescence In Situ Hybridization (FISH)
- Immunohistochemistry (IHC)
- Lung Cancer
- Colorectal Cancer
- Breast Cancer
- Others
- AmoyDx
- Novogene
- Illumina
- Roche
- Agilent
- Abbott
- Thermo Fisher
- Qiagen
- Guardant Health
- North America (United States, Canada, and Mexico)
- Europe (Germany, France, UK, Russia, Italy, and Rest of Europe)
- Asia-Pacific (China, Japan, South Korea, India, Southeast Asia, Australia and Rest of Asia-Pacific)
- South America (Brazil, Argentina and Rest of South America)
- Middle East & Africa (Turkey, Saudi Arabia, UAE, Rest of Middle East & Africa)
Chapter 1, to describe Cancer Companion Diagnostic product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top players of Cancer Companion Diagnostic, with revenue, gross margin and global market share of Cancer Companion Diagnostic from 2018 to 2023.
Chapter 3, the Cancer Companion Diagnostic competitive situation, revenue and global market share of top players are analyzed emphatically by landscape contrast.
Chapter 4 and 5, to segment the market size by Type and application, with consumption value and growth rate by Type, application, from 2018 to 2029.
Chapter 6, 7, 8, 9, and 10, to break the market size data at the country level, with revenue and market share for key countries in the world, from 2018 to 2023.and Cancer Companion Diagnostic market forecast, by regions, type and application, with consumption value, from 2024 to 2029.
Chapter 11, market dynamics, drivers, restraints, trends and Porters Five Forces analysis.
Chapter 12, the key raw materials and key suppliers, and industry chain of Cancer Companion Diagnostic.
Chapter 13, to describe Cancer Companion Diagnostic research findings and conclusion.
1 MARKET OVERVIEW
1.1 Product Overview and Scope of Cancer Companion Diagnostic
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Cancer Companion Diagnostic by Type
1.3.1 Overview: Global Cancer Companion Diagnostic Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Cancer Companion Diagnostic Consumption Value Market Share by Type in 2022
1.3.3 Polymerase Chain Reaction (PCR)
1.3.4 “Next Generation” Sequencing (NGS)
1.3.5 Fluorescence In Situ Hybridization (FISH)
1.3.6 Immunohistochemistry (IHC)
1.4 Global Cancer Companion Diagnostic Market by Application
1.4.1 Overview: Global Cancer Companion Diagnostic Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Lung Cancer
1.4.3 Colorectal Cancer
1.4.4 Breast Cancer
1.4.5 Others
1.5 Global Cancer Companion Diagnostic Market Size & Forecast
1.6 Global Cancer Companion Diagnostic Market Size and Forecast by Region
1.6.1 Global Cancer Companion Diagnostic Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Cancer Companion Diagnostic Market Size by Region, (2018-2029)
1.6.3 North America Cancer Companion Diagnostic Market Size and Prospect (2018-2029)
1.6.4 Europe Cancer Companion Diagnostic Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Cancer Companion Diagnostic Market Size and Prospect (2018-2029)
1.6.6 South America Cancer Companion Diagnostic Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Cancer Companion Diagnostic Market Size and Prospect (2018-2029)
2 COMPANY PROFILES
2.1 AmoyDx
2.1.1 AmoyDx Details
2.1.2 AmoyDx Major Business
2.1.3 AmoyDx Cancer Companion Diagnostic Product and Solutions
2.1.4 AmoyDx Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 AmoyDx Recent Developments and Future Plans
2.2 Novogene
2.2.1 Novogene Details
2.2.2 Novogene Major Business
2.2.3 Novogene Cancer Companion Diagnostic Product and Solutions
2.2.4 Novogene Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Novogene Recent Developments and Future Plans
2.3 Illumina
2.3.1 Illumina Details
2.3.2 Illumina Major Business
2.3.3 Illumina Cancer Companion Diagnostic Product and Solutions
2.3.4 Illumina Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Illumina Recent Developments and Future Plans
2.4 Roche
2.4.1 Roche Details
2.4.2 Roche Major Business
2.4.3 Roche Cancer Companion Diagnostic Product and Solutions
2.4.4 Roche Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Roche Recent Developments and Future Plans
2.5 Agilent
2.5.1 Agilent Details
2.5.2 Agilent Major Business
2.5.3 Agilent Cancer Companion Diagnostic Product and Solutions
2.5.4 Agilent Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Agilent Recent Developments and Future Plans
2.6 Abbott
2.6.1 Abbott Details
2.6.2 Abbott Major Business
2.6.3 Abbott Cancer Companion Diagnostic Product and Solutions
2.6.4 Abbott Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Abbott Recent Developments and Future Plans
2.7 Thermo Fisher
2.7.1 Thermo Fisher Details
2.7.2 Thermo Fisher Major Business
2.7.3 Thermo Fisher Cancer Companion Diagnostic Product and Solutions
2.7.4 Thermo Fisher Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Thermo Fisher Recent Developments and Future Plans
2.8 Qiagen
2.8.1 Qiagen Details
2.8.2 Qiagen Major Business
2.8.3 Qiagen Cancer Companion Diagnostic Product and Solutions
2.8.4 Qiagen Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Qiagen Recent Developments and Future Plans
2.9 Guardant Health
2.9.1 Guardant Health Details
2.9.2 Guardant Health Major Business
2.9.3 Guardant Health Cancer Companion Diagnostic Product and Solutions
2.9.4 Guardant Health Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Guardant Health Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Cancer Companion Diagnostic Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Cancer Companion Diagnostic by Company Revenue
3.2.2 Top 3 Cancer Companion Diagnostic Players Market Share in 2022
3.2.3 Top 6 Cancer Companion Diagnostic Players Market Share in 2022
3.3 Cancer Companion Diagnostic Market: Overall Company Footprint Analysis
3.3.1 Cancer Companion Diagnostic Market: Region Footprint
3.3.2 Cancer Companion Diagnostic Market: Company Product Type Footprint
3.3.3 Cancer Companion Diagnostic Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Cancer Companion Diagnostic Consumption Value and Market Share by Type (2018-2023)
4.2 Global Cancer Companion Diagnostic Market Forecast by Type (2024-2029)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Cancer Companion Diagnostic Consumption Value Market Share by Application (2018-2023)
5.2 Global Cancer Companion Diagnostic Market Forecast by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Cancer Companion Diagnostic Consumption Value by Type (2018-2029)
6.2 North America Cancer Companion Diagnostic Consumption Value by Application (2018-2029)
6.3 North America Cancer Companion Diagnostic Market Size by Country
6.3.1 North America Cancer Companion Diagnostic Consumption Value by Country (2018-2029)
6.3.2 United States Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
6.3.3 Canada Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
6.3.4 Mexico Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
7 EUROPE
7.1 Europe Cancer Companion Diagnostic Consumption Value by Type (2018-2029)
7.2 Europe Cancer Companion Diagnostic Consumption Value by Application (2018-2029)
7.3 Europe Cancer Companion Diagnostic Market Size by Country
7.3.1 Europe Cancer Companion Diagnostic Consumption Value by Country (2018-2029)
7.3.2 Germany Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
7.3.3 France Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
7.3.5 Russia Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
7.3.6 Italy Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
8 ASIA-PACIFIC
8.1 Asia-Pacific Cancer Companion Diagnostic Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Cancer Companion Diagnostic Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Cancer Companion Diagnostic Market Size by Region
8.3.1 Asia-Pacific Cancer Companion Diagnostic Consumption Value by Region (2018-2029)
8.3.2 China Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
8.3.3 Japan Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
8.3.4 South Korea Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
8.3.5 India Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
8.3.7 Australia Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
9 SOUTH AMERICA
9.1 South America Cancer Companion Diagnostic Consumption Value by Type (2018-2029)
9.2 South America Cancer Companion Diagnostic Consumption Value by Application (2018-2029)
9.3 South America Cancer Companion Diagnostic Market Size by Country
9.3.1 South America Cancer Companion Diagnostic Consumption Value by Country (2018-2029)
9.3.2 Brazil Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
9.3.3 Argentina Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Cancer Companion Diagnostic Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Cancer Companion Diagnostic Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Cancer Companion Diagnostic Market Size by Country
10.3.1 Middle East & Africa Cancer Companion Diagnostic Consumption Value by Country (2018-2029)
10.3.2 Turkey Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
10.3.4 UAE Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
11 MARKET DYNAMICS
11.1 Cancer Companion Diagnostic Market Drivers
11.2 Cancer Companion Diagnostic Market Restraints
11.3 Cancer Companion Diagnostic Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Cancer Companion Diagnostic Industry Chain
12.2 Cancer Companion Diagnostic Upstream Analysis
12.3 Cancer Companion Diagnostic Midstream Analysis
12.4 Cancer Companion Diagnostic Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
1.1 Product Overview and Scope of Cancer Companion Diagnostic
1.2 Market Estimation Caveats and Base Year
1.3 Classification of Cancer Companion Diagnostic by Type
1.3.1 Overview: Global Cancer Companion Diagnostic Market Size by Type: 2018 Versus 2022 Versus 2029
1.3.2 Global Cancer Companion Diagnostic Consumption Value Market Share by Type in 2022
1.3.3 Polymerase Chain Reaction (PCR)
1.3.4 “Next Generation” Sequencing (NGS)
1.3.5 Fluorescence In Situ Hybridization (FISH)
1.3.6 Immunohistochemistry (IHC)
1.4 Global Cancer Companion Diagnostic Market by Application
1.4.1 Overview: Global Cancer Companion Diagnostic Market Size by Application: 2018 Versus 2022 Versus 2029
1.4.2 Lung Cancer
1.4.3 Colorectal Cancer
1.4.4 Breast Cancer
1.4.5 Others
1.5 Global Cancer Companion Diagnostic Market Size & Forecast
1.6 Global Cancer Companion Diagnostic Market Size and Forecast by Region
1.6.1 Global Cancer Companion Diagnostic Market Size by Region: 2018 VS 2022 VS 2029
1.6.2 Global Cancer Companion Diagnostic Market Size by Region, (2018-2029)
1.6.3 North America Cancer Companion Diagnostic Market Size and Prospect (2018-2029)
1.6.4 Europe Cancer Companion Diagnostic Market Size and Prospect (2018-2029)
1.6.5 Asia-Pacific Cancer Companion Diagnostic Market Size and Prospect (2018-2029)
1.6.6 South America Cancer Companion Diagnostic Market Size and Prospect (2018-2029)
1.6.7 Middle East and Africa Cancer Companion Diagnostic Market Size and Prospect (2018-2029)
2 COMPANY PROFILES
2.1 AmoyDx
2.1.1 AmoyDx Details
2.1.2 AmoyDx Major Business
2.1.3 AmoyDx Cancer Companion Diagnostic Product and Solutions
2.1.4 AmoyDx Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023)
2.1.5 AmoyDx Recent Developments and Future Plans
2.2 Novogene
2.2.1 Novogene Details
2.2.2 Novogene Major Business
2.2.3 Novogene Cancer Companion Diagnostic Product and Solutions
2.2.4 Novogene Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023)
2.2.5 Novogene Recent Developments and Future Plans
2.3 Illumina
2.3.1 Illumina Details
2.3.2 Illumina Major Business
2.3.3 Illumina Cancer Companion Diagnostic Product and Solutions
2.3.4 Illumina Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023)
2.3.5 Illumina Recent Developments and Future Plans
2.4 Roche
2.4.1 Roche Details
2.4.2 Roche Major Business
2.4.3 Roche Cancer Companion Diagnostic Product and Solutions
2.4.4 Roche Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023)
2.4.5 Roche Recent Developments and Future Plans
2.5 Agilent
2.5.1 Agilent Details
2.5.2 Agilent Major Business
2.5.3 Agilent Cancer Companion Diagnostic Product and Solutions
2.5.4 Agilent Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023)
2.5.5 Agilent Recent Developments and Future Plans
2.6 Abbott
2.6.1 Abbott Details
2.6.2 Abbott Major Business
2.6.3 Abbott Cancer Companion Diagnostic Product and Solutions
2.6.4 Abbott Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023)
2.6.5 Abbott Recent Developments and Future Plans
2.7 Thermo Fisher
2.7.1 Thermo Fisher Details
2.7.2 Thermo Fisher Major Business
2.7.3 Thermo Fisher Cancer Companion Diagnostic Product and Solutions
2.7.4 Thermo Fisher Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023)
2.7.5 Thermo Fisher Recent Developments and Future Plans
2.8 Qiagen
2.8.1 Qiagen Details
2.8.2 Qiagen Major Business
2.8.3 Qiagen Cancer Companion Diagnostic Product and Solutions
2.8.4 Qiagen Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023)
2.8.5 Qiagen Recent Developments and Future Plans
2.9 Guardant Health
2.9.1 Guardant Health Details
2.9.2 Guardant Health Major Business
2.9.3 Guardant Health Cancer Companion Diagnostic Product and Solutions
2.9.4 Guardant Health Cancer Companion Diagnostic Revenue, Gross Margin and Market Share (2018-2023)
2.9.5 Guardant Health Recent Developments and Future Plans
3 MARKET COMPETITION, BY PLAYERS
3.1 Global Cancer Companion Diagnostic Revenue and Share by Players (2018-2023)
3.2 Market Share Analysis (2022)
3.2.1 Market Share of Cancer Companion Diagnostic by Company Revenue
3.2.2 Top 3 Cancer Companion Diagnostic Players Market Share in 2022
3.2.3 Top 6 Cancer Companion Diagnostic Players Market Share in 2022
3.3 Cancer Companion Diagnostic Market: Overall Company Footprint Analysis
3.3.1 Cancer Companion Diagnostic Market: Region Footprint
3.3.2 Cancer Companion Diagnostic Market: Company Product Type Footprint
3.3.3 Cancer Companion Diagnostic Market: Company Product Application Footprint
3.4 New Market Entrants and Barriers to Market Entry
3.5 Mergers, Acquisition, Agreements, and Collaborations
4 MARKET SIZE SEGMENT BY TYPE
4.1 Global Cancer Companion Diagnostic Consumption Value and Market Share by Type (2018-2023)
4.2 Global Cancer Companion Diagnostic Market Forecast by Type (2024-2029)
5 MARKET SIZE SEGMENT BY APPLICATION
5.1 Global Cancer Companion Diagnostic Consumption Value Market Share by Application (2018-2023)
5.2 Global Cancer Companion Diagnostic Market Forecast by Application (2024-2029)
6 NORTH AMERICA
6.1 North America Cancer Companion Diagnostic Consumption Value by Type (2018-2029)
6.2 North America Cancer Companion Diagnostic Consumption Value by Application (2018-2029)
6.3 North America Cancer Companion Diagnostic Market Size by Country
6.3.1 North America Cancer Companion Diagnostic Consumption Value by Country (2018-2029)
6.3.2 United States Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
6.3.3 Canada Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
6.3.4 Mexico Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
7 EUROPE
7.1 Europe Cancer Companion Diagnostic Consumption Value by Type (2018-2029)
7.2 Europe Cancer Companion Diagnostic Consumption Value by Application (2018-2029)
7.3 Europe Cancer Companion Diagnostic Market Size by Country
7.3.1 Europe Cancer Companion Diagnostic Consumption Value by Country (2018-2029)
7.3.2 Germany Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
7.3.3 France Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
7.3.4 United Kingdom Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
7.3.5 Russia Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
7.3.6 Italy Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
8 ASIA-PACIFIC
8.1 Asia-Pacific Cancer Companion Diagnostic Consumption Value by Type (2018-2029)
8.2 Asia-Pacific Cancer Companion Diagnostic Consumption Value by Application (2018-2029)
8.3 Asia-Pacific Cancer Companion Diagnostic Market Size by Region
8.3.1 Asia-Pacific Cancer Companion Diagnostic Consumption Value by Region (2018-2029)
8.3.2 China Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
8.3.3 Japan Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
8.3.4 South Korea Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
8.3.5 India Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
8.3.6 Southeast Asia Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
8.3.7 Australia Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
9 SOUTH AMERICA
9.1 South America Cancer Companion Diagnostic Consumption Value by Type (2018-2029)
9.2 South America Cancer Companion Diagnostic Consumption Value by Application (2018-2029)
9.3 South America Cancer Companion Diagnostic Market Size by Country
9.3.1 South America Cancer Companion Diagnostic Consumption Value by Country (2018-2029)
9.3.2 Brazil Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
9.3.3 Argentina Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
10 MIDDLE EAST & AFRICA
10.1 Middle East & Africa Cancer Companion Diagnostic Consumption Value by Type (2018-2029)
10.2 Middle East & Africa Cancer Companion Diagnostic Consumption Value by Application (2018-2029)
10.3 Middle East & Africa Cancer Companion Diagnostic Market Size by Country
10.3.1 Middle East & Africa Cancer Companion Diagnostic Consumption Value by Country (2018-2029)
10.3.2 Turkey Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
10.3.3 Saudi Arabia Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
10.3.4 UAE Cancer Companion Diagnostic Market Size and Forecast (2018-2029)
11 MARKET DYNAMICS
11.1 Cancer Companion Diagnostic Market Drivers
11.2 Cancer Companion Diagnostic Market Restraints
11.3 Cancer Companion Diagnostic Trends Analysis
11.4 Porters Five Forces Analysis
11.4.1 Threat of New Entrants
11.4.2 Bargaining Power of Suppliers
11.4.3 Bargaining Power of Buyers
11.4.4 Threat of Substitutes
11.4.5 Competitive Rivalry
12 INDUSTRY CHAIN ANALYSIS
12.1 Cancer Companion Diagnostic Industry Chain
12.2 Cancer Companion Diagnostic Upstream Analysis
12.3 Cancer Companion Diagnostic Midstream Analysis
12.4 Cancer Companion Diagnostic Downstream Analysis
13 RESEARCH FINDINGS AND CONCLUSION
14 APPENDIX
14.1 Methodology
14.2 Research Process and Data Source
14.3 Disclaimer
LIST OF TABLES
Table 1. Global Cancer Companion Diagnostic Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Cancer Companion Diagnostic Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Cancer Companion Diagnostic Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Cancer Companion Diagnostic Consumption Value by Region (2024-2029) & (USD Million)
Table 5. AmoyDx Company Information, Head Office, and Major Competitors
Table 6. AmoyDx Major Business
Table 7. AmoyDx Cancer Companion Diagnostic Product and Solutions
Table 8. AmoyDx Cancer Companion Diagnostic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. AmoyDx Recent Developments and Future Plans
Table 10. Novogene Company Information, Head Office, and Major Competitors
Table 11. Novogene Major Business
Table 12. Novogene Cancer Companion Diagnostic Product and Solutions
Table 13. Novogene Cancer Companion Diagnostic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Novogene Recent Developments and Future Plans
Table 15. Illumina Company Information, Head Office, and Major Competitors
Table 16. Illumina Major Business
Table 17. Illumina Cancer Companion Diagnostic Product and Solutions
Table 18. Illumina Cancer Companion Diagnostic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Illumina Recent Developments and Future Plans
Table 20. Roche Company Information, Head Office, and Major Competitors
Table 21. Roche Major Business
Table 22. Roche Cancer Companion Diagnostic Product and Solutions
Table 23. Roche Cancer Companion Diagnostic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Roche Recent Developments and Future Plans
Table 25. Agilent Company Information, Head Office, and Major Competitors
Table 26. Agilent Major Business
Table 27. Agilent Cancer Companion Diagnostic Product and Solutions
Table 28. Agilent Cancer Companion Diagnostic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Agilent Recent Developments and Future Plans
Table 30. Abbott Company Information, Head Office, and Major Competitors
Table 31. Abbott Major Business
Table 32. Abbott Cancer Companion Diagnostic Product and Solutions
Table 33. Abbott Cancer Companion Diagnostic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Abbott Recent Developments and Future Plans
Table 35. Thermo Fisher Company Information, Head Office, and Major Competitors
Table 36. Thermo Fisher Major Business
Table 37. Thermo Fisher Cancer Companion Diagnostic Product and Solutions
Table 38. Thermo Fisher Cancer Companion Diagnostic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Thermo Fisher Recent Developments and Future Plans
Table 40. Qiagen Company Information, Head Office, and Major Competitors
Table 41. Qiagen Major Business
Table 42. Qiagen Cancer Companion Diagnostic Product and Solutions
Table 43. Qiagen Cancer Companion Diagnostic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Qiagen Recent Developments and Future Plans
Table 45. Guardant Health Company Information, Head Office, and Major Competitors
Table 46. Guardant Health Major Business
Table 47. Guardant Health Cancer Companion Diagnostic Product and Solutions
Table 48. Guardant Health Cancer Companion Diagnostic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Guardant Health Recent Developments and Future Plans
Table 50. Global Cancer Companion Diagnostic Revenue (USD Million) by Players (2018-2023)
Table 51. Global Cancer Companion Diagnostic Revenue Share by Players (2018-2023)
Table 52. Breakdown of Cancer Companion Diagnostic by Company Type (Tier 1, Tier 2, and Tier 3)
Table 53. Market Position of Players in Cancer Companion Diagnostic, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 54. Head Office of Key Cancer Companion Diagnostic Players
Table 55. Cancer Companion Diagnostic Market: Company Product Type Footprint
Table 56. Cancer Companion Diagnostic Market: Company Product Application Footprint
Table 57. Cancer Companion Diagnostic New Market Entrants and Barriers to Market Entry
Table 58. Cancer Companion Diagnostic Mergers, Acquisition, Agreements, and Collaborations
Table 59. Global Cancer Companion Diagnostic Consumption Value (USD Million) by Type (2018-2023)
Table 60. Global Cancer Companion Diagnostic Consumption Value Share by Type (2018-2023)
Table 61. Global Cancer Companion Diagnostic Consumption Value Forecast by Type (2024-2029)
Table 62. Global Cancer Companion Diagnostic Consumption Value by Application (2018-2023)
Table 63. Global Cancer Companion Diagnostic Consumption Value Forecast by Application (2024-2029)
Table 64. North America Cancer Companion Diagnostic Consumption Value by Type (2018-2023) & (USD Million)
Table 65. North America Cancer Companion Diagnostic Consumption Value by Type (2024-2029) & (USD Million)
Table 66. North America Cancer Companion Diagnostic Consumption Value by Application (2018-2023) & (USD Million)
Table 67. North America Cancer Companion Diagnostic Consumption Value by Application (2024-2029) & (USD Million)
Table 68. North America Cancer Companion Diagnostic Consumption Value by Country (2018-2023) & (USD Million)
Table 69. North America Cancer Companion Diagnostic Consumption Value by Country (2024-2029) & (USD Million)
Table 70. Europe Cancer Companion Diagnostic Consumption Value by Type (2018-2023) & (USD Million)
Table 71. Europe Cancer Companion Diagnostic Consumption Value by Type (2024-2029) & (USD Million)
Table 72. Europe Cancer Companion Diagnostic Consumption Value by Application (2018-2023) & (USD Million)
Table 73. Europe Cancer Companion Diagnostic Consumption Value by Application (2024-2029) & (USD Million)
Table 74. Europe Cancer Companion Diagnostic Consumption Value by Country (2018-2023) & (USD Million)
Table 75. Europe Cancer Companion Diagnostic Consumption Value by Country (2024-2029) & (USD Million)
Table 76. Asia-Pacific Cancer Companion Diagnostic Consumption Value by Type (2018-2023) & (USD Million)
Table 77. Asia-Pacific Cancer Companion Diagnostic Consumption Value by Type (2024-2029) & (USD Million)
Table 78. Asia-Pacific Cancer Companion Diagnostic Consumption Value by Application (2018-2023) & (USD Million)
Table 79. Asia-Pacific Cancer Companion Diagnostic Consumption Value by Application (2024-2029) & (USD Million)
Table 80. Asia-Pacific Cancer Companion Diagnostic Consumption Value by Region (2018-2023) & (USD Million)
Table 81. Asia-Pacific Cancer Companion Diagnostic Consumption Value by Region (2024-2029) & (USD Million)
Table 82. South America Cancer Companion Diagnostic Consumption Value by Type (2018-2023) & (USD Million)
Table 83. South America Cancer Companion Diagnostic Consumption Value by Type (2024-2029) & (USD Million)
Table 84. South America Cancer Companion Diagnostic Consumption Value by Application (2018-2023) & (USD Million)
Table 85. South America Cancer Companion Diagnostic Consumption Value by Application (2024-2029) & (USD Million)
Table 86. South America Cancer Companion Diagnostic Consumption Value by Country (2018-2023) & (USD Million)
Table 87. South America Cancer Companion Diagnostic Consumption Value by Country (2024-2029) & (USD Million)
Table 88. Middle East & Africa Cancer Companion Diagnostic Consumption Value by Type (2018-2023) & (USD Million)
Table 89. Middle East & Africa Cancer Companion Diagnostic Consumption Value by Type (2024-2029) & (USD Million)
Table 90. Middle East & Africa Cancer Companion Diagnostic Consumption Value by Application (2018-2023) & (USD Million)
Table 91. Middle East & Africa Cancer Companion Diagnostic Consumption Value by Application (2024-2029) & (USD Million)
Table 92. Middle East & Africa Cancer Companion Diagnostic Consumption Value by Country (2018-2023) & (USD Million)
Table 93. Middle East & Africa Cancer Companion Diagnostic Consumption Value by Country (2024-2029) & (USD Million)
Table 94. Cancer Companion Diagnostic Raw Material
Table 95. Key Suppliers of Cancer Companion Diagnostic Raw Materials
Table 1. Global Cancer Companion Diagnostic Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Table 2. Global Cancer Companion Diagnostic Consumption Value by Application, (USD Million), 2018 & 2022 & 2029
Table 3. Global Cancer Companion Diagnostic Consumption Value by Region (2018-2023) & (USD Million)
Table 4. Global Cancer Companion Diagnostic Consumption Value by Region (2024-2029) & (USD Million)
Table 5. AmoyDx Company Information, Head Office, and Major Competitors
Table 6. AmoyDx Major Business
Table 7. AmoyDx Cancer Companion Diagnostic Product and Solutions
Table 8. AmoyDx Cancer Companion Diagnostic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 9. AmoyDx Recent Developments and Future Plans
Table 10. Novogene Company Information, Head Office, and Major Competitors
Table 11. Novogene Major Business
Table 12. Novogene Cancer Companion Diagnostic Product and Solutions
Table 13. Novogene Cancer Companion Diagnostic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 14. Novogene Recent Developments and Future Plans
Table 15. Illumina Company Information, Head Office, and Major Competitors
Table 16. Illumina Major Business
Table 17. Illumina Cancer Companion Diagnostic Product and Solutions
Table 18. Illumina Cancer Companion Diagnostic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 19. Illumina Recent Developments and Future Plans
Table 20. Roche Company Information, Head Office, and Major Competitors
Table 21. Roche Major Business
Table 22. Roche Cancer Companion Diagnostic Product and Solutions
Table 23. Roche Cancer Companion Diagnostic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 24. Roche Recent Developments and Future Plans
Table 25. Agilent Company Information, Head Office, and Major Competitors
Table 26. Agilent Major Business
Table 27. Agilent Cancer Companion Diagnostic Product and Solutions
Table 28. Agilent Cancer Companion Diagnostic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 29. Agilent Recent Developments and Future Plans
Table 30. Abbott Company Information, Head Office, and Major Competitors
Table 31. Abbott Major Business
Table 32. Abbott Cancer Companion Diagnostic Product and Solutions
Table 33. Abbott Cancer Companion Diagnostic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 34. Abbott Recent Developments and Future Plans
Table 35. Thermo Fisher Company Information, Head Office, and Major Competitors
Table 36. Thermo Fisher Major Business
Table 37. Thermo Fisher Cancer Companion Diagnostic Product and Solutions
Table 38. Thermo Fisher Cancer Companion Diagnostic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 39. Thermo Fisher Recent Developments and Future Plans
Table 40. Qiagen Company Information, Head Office, and Major Competitors
Table 41. Qiagen Major Business
Table 42. Qiagen Cancer Companion Diagnostic Product and Solutions
Table 43. Qiagen Cancer Companion Diagnostic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 44. Qiagen Recent Developments and Future Plans
Table 45. Guardant Health Company Information, Head Office, and Major Competitors
Table 46. Guardant Health Major Business
Table 47. Guardant Health Cancer Companion Diagnostic Product and Solutions
Table 48. Guardant Health Cancer Companion Diagnostic Revenue (USD Million), Gross Margin and Market Share (2018-2023)
Table 49. Guardant Health Recent Developments and Future Plans
Table 50. Global Cancer Companion Diagnostic Revenue (USD Million) by Players (2018-2023)
Table 51. Global Cancer Companion Diagnostic Revenue Share by Players (2018-2023)
Table 52. Breakdown of Cancer Companion Diagnostic by Company Type (Tier 1, Tier 2, and Tier 3)
Table 53. Market Position of Players in Cancer Companion Diagnostic, (Tier 1, Tier 2, and Tier 3), Based on Revenue in 2022
Table 54. Head Office of Key Cancer Companion Diagnostic Players
Table 55. Cancer Companion Diagnostic Market: Company Product Type Footprint
Table 56. Cancer Companion Diagnostic Market: Company Product Application Footprint
Table 57. Cancer Companion Diagnostic New Market Entrants and Barriers to Market Entry
Table 58. Cancer Companion Diagnostic Mergers, Acquisition, Agreements, and Collaborations
Table 59. Global Cancer Companion Diagnostic Consumption Value (USD Million) by Type (2018-2023)
Table 60. Global Cancer Companion Diagnostic Consumption Value Share by Type (2018-2023)
Table 61. Global Cancer Companion Diagnostic Consumption Value Forecast by Type (2024-2029)
Table 62. Global Cancer Companion Diagnostic Consumption Value by Application (2018-2023)
Table 63. Global Cancer Companion Diagnostic Consumption Value Forecast by Application (2024-2029)
Table 64. North America Cancer Companion Diagnostic Consumption Value by Type (2018-2023) & (USD Million)
Table 65. North America Cancer Companion Diagnostic Consumption Value by Type (2024-2029) & (USD Million)
Table 66. North America Cancer Companion Diagnostic Consumption Value by Application (2018-2023) & (USD Million)
Table 67. North America Cancer Companion Diagnostic Consumption Value by Application (2024-2029) & (USD Million)
Table 68. North America Cancer Companion Diagnostic Consumption Value by Country (2018-2023) & (USD Million)
Table 69. North America Cancer Companion Diagnostic Consumption Value by Country (2024-2029) & (USD Million)
Table 70. Europe Cancer Companion Diagnostic Consumption Value by Type (2018-2023) & (USD Million)
Table 71. Europe Cancer Companion Diagnostic Consumption Value by Type (2024-2029) & (USD Million)
Table 72. Europe Cancer Companion Diagnostic Consumption Value by Application (2018-2023) & (USD Million)
Table 73. Europe Cancer Companion Diagnostic Consumption Value by Application (2024-2029) & (USD Million)
Table 74. Europe Cancer Companion Diagnostic Consumption Value by Country (2018-2023) & (USD Million)
Table 75. Europe Cancer Companion Diagnostic Consumption Value by Country (2024-2029) & (USD Million)
Table 76. Asia-Pacific Cancer Companion Diagnostic Consumption Value by Type (2018-2023) & (USD Million)
Table 77. Asia-Pacific Cancer Companion Diagnostic Consumption Value by Type (2024-2029) & (USD Million)
Table 78. Asia-Pacific Cancer Companion Diagnostic Consumption Value by Application (2018-2023) & (USD Million)
Table 79. Asia-Pacific Cancer Companion Diagnostic Consumption Value by Application (2024-2029) & (USD Million)
Table 80. Asia-Pacific Cancer Companion Diagnostic Consumption Value by Region (2018-2023) & (USD Million)
Table 81. Asia-Pacific Cancer Companion Diagnostic Consumption Value by Region (2024-2029) & (USD Million)
Table 82. South America Cancer Companion Diagnostic Consumption Value by Type (2018-2023) & (USD Million)
Table 83. South America Cancer Companion Diagnostic Consumption Value by Type (2024-2029) & (USD Million)
Table 84. South America Cancer Companion Diagnostic Consumption Value by Application (2018-2023) & (USD Million)
Table 85. South America Cancer Companion Diagnostic Consumption Value by Application (2024-2029) & (USD Million)
Table 86. South America Cancer Companion Diagnostic Consumption Value by Country (2018-2023) & (USD Million)
Table 87. South America Cancer Companion Diagnostic Consumption Value by Country (2024-2029) & (USD Million)
Table 88. Middle East & Africa Cancer Companion Diagnostic Consumption Value by Type (2018-2023) & (USD Million)
Table 89. Middle East & Africa Cancer Companion Diagnostic Consumption Value by Type (2024-2029) & (USD Million)
Table 90. Middle East & Africa Cancer Companion Diagnostic Consumption Value by Application (2018-2023) & (USD Million)
Table 91. Middle East & Africa Cancer Companion Diagnostic Consumption Value by Application (2024-2029) & (USD Million)
Table 92. Middle East & Africa Cancer Companion Diagnostic Consumption Value by Country (2018-2023) & (USD Million)
Table 93. Middle East & Africa Cancer Companion Diagnostic Consumption Value by Country (2024-2029) & (USD Million)
Table 94. Cancer Companion Diagnostic Raw Material
Table 95. Key Suppliers of Cancer Companion Diagnostic Raw Materials
LIST OF FIGURES
Figure 1. Cancer Companion Diagnostic Picture
Figure 2. Global Cancer Companion Diagnostic Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Cancer Companion Diagnostic Consumption Value Market Share by Type in 2022
Figure 4. Polymerase Chain Reaction (PCR)
Figure 5. “Next Generation” Sequencing (NGS)
Figure 6. Fluorescence In Situ Hybridization (FISH)
Figure 7. Immunohistochemistry (IHC)
Figure 8. Global Cancer Companion Diagnostic Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 9. Cancer Companion Diagnostic Consumption Value Market Share by Application in 2022
Figure 10. Lung Cancer Picture
Figure 11. Colorectal Cancer Picture
Figure 12. Breast Cancer Picture
Figure 13. Others Picture
Figure 14. Global Cancer Companion Diagnostic Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 15. Global Cancer Companion Diagnostic Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 16. Global Market Cancer Companion Diagnostic Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 17. Global Cancer Companion Diagnostic Consumption Value Market Share by Region (2018-2029)
Figure 18. Global Cancer Companion Diagnostic Consumption Value Market Share by Region in 2022
Figure 19. North America Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 20. Europe Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 21. Asia-Pacific Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 22. South America Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 23. Middle East and Africa Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 24. Global Cancer Companion Diagnostic Revenue Share by Players in 2022
Figure 25. Cancer Companion Diagnostic Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 26. Global Top 3 Players Cancer Companion Diagnostic Market Share in 2022
Figure 27. Global Top 6 Players Cancer Companion Diagnostic Market Share in 2022
Figure 28. Global Cancer Companion Diagnostic Consumption Value Share by Type (2018-2023)
Figure 29. Global Cancer Companion Diagnostic Market Share Forecast by Type (2024-2029)
Figure 30. Global Cancer Companion Diagnostic Consumption Value Share by Application (2018-2023)
Figure 31. Global Cancer Companion Diagnostic Market Share Forecast by Application (2024-2029)
Figure 32. North America Cancer Companion Diagnostic Consumption Value Market Share by Type (2018-2029)
Figure 33. North America Cancer Companion Diagnostic Consumption Value Market Share by Application (2018-2029)
Figure 34. North America Cancer Companion Diagnostic Consumption Value Market Share by Country (2018-2029)
Figure 35. United States Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 36. Canada Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 37. Mexico Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 38. Europe Cancer Companion Diagnostic Consumption Value Market Share by Type (2018-2029)
Figure 39. Europe Cancer Companion Diagnostic Consumption Value Market Share by Application (2018-2029)
Figure 40. Europe Cancer Companion Diagnostic Consumption Value Market Share by Country (2018-2029)
Figure 41. Germany Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 42. France Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 43. United Kingdom Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 44. Russia Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 45. Italy Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 46. Asia-Pacific Cancer Companion Diagnostic Consumption Value Market Share by Type (2018-2029)
Figure 47. Asia-Pacific Cancer Companion Diagnostic Consumption Value Market Share by Application (2018-2029)
Figure 48. Asia-Pacific Cancer Companion Diagnostic Consumption Value Market Share by Region (2018-2029)
Figure 49. China Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 50. Japan Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 51. South Korea Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 52. India Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 53. Southeast Asia Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 54. Australia Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 55. South America Cancer Companion Diagnostic Consumption Value Market Share by Type (2018-2029)
Figure 56. South America Cancer Companion Diagnostic Consumption Value Market Share by Application (2018-2029)
Figure 57. South America Cancer Companion Diagnostic Consumption Value Market Share by Country (2018-2029)
Figure 58. Brazil Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 59. Argentina Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 60. Middle East and Africa Cancer Companion Diagnostic Consumption Value Market Share by Type (2018-2029)
Figure 61. Middle East and Africa Cancer Companion Diagnostic Consumption Value Market Share by Application (2018-2029)
Figure 62. Middle East and Africa Cancer Companion Diagnostic Consumption Value Market Share by Country (2018-2029)
Figure 63. Turkey Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 64. Saudi Arabia Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 65. UAE Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 66. Cancer Companion Diagnostic Market Drivers
Figure 67. Cancer Companion Diagnostic Market Restraints
Figure 68. Cancer Companion Diagnostic Market Trends
Figure 69. Porters Five Forces Analysis
Figure 70. Manufacturing Cost Structure Analysis of Cancer Companion Diagnostic in 2022
Figure 71. Manufacturing Process Analysis of Cancer Companion Diagnostic
Figure 72. Cancer Companion Diagnostic Industrial Chain
Figure 73. Methodology
Figure 74. Research Process and Data Source
Figure 1. Cancer Companion Diagnostic Picture
Figure 2. Global Cancer Companion Diagnostic Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 3. Global Cancer Companion Diagnostic Consumption Value Market Share by Type in 2022
Figure 4. Polymerase Chain Reaction (PCR)
Figure 5. “Next Generation” Sequencing (NGS)
Figure 6. Fluorescence In Situ Hybridization (FISH)
Figure 7. Immunohistochemistry (IHC)
Figure 8. Global Cancer Companion Diagnostic Consumption Value by Type, (USD Million), 2018 & 2022 & 2029
Figure 9. Cancer Companion Diagnostic Consumption Value Market Share by Application in 2022
Figure 10. Lung Cancer Picture
Figure 11. Colorectal Cancer Picture
Figure 12. Breast Cancer Picture
Figure 13. Others Picture
Figure 14. Global Cancer Companion Diagnostic Consumption Value, (USD Million): 2018 & 2022 & 2029
Figure 15. Global Cancer Companion Diagnostic Consumption Value and Forecast (2018-2029) & (USD Million)
Figure 16. Global Market Cancer Companion Diagnostic Consumption Value (USD Million) Comparison by Region (2018 & 2022 & 2029)
Figure 17. Global Cancer Companion Diagnostic Consumption Value Market Share by Region (2018-2029)
Figure 18. Global Cancer Companion Diagnostic Consumption Value Market Share by Region in 2022
Figure 19. North America Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 20. Europe Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 21. Asia-Pacific Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 22. South America Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 23. Middle East and Africa Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 24. Global Cancer Companion Diagnostic Revenue Share by Players in 2022
Figure 25. Cancer Companion Diagnostic Market Share by Company Type (Tier 1, Tier 2 and Tier 3) in 2022
Figure 26. Global Top 3 Players Cancer Companion Diagnostic Market Share in 2022
Figure 27. Global Top 6 Players Cancer Companion Diagnostic Market Share in 2022
Figure 28. Global Cancer Companion Diagnostic Consumption Value Share by Type (2018-2023)
Figure 29. Global Cancer Companion Diagnostic Market Share Forecast by Type (2024-2029)
Figure 30. Global Cancer Companion Diagnostic Consumption Value Share by Application (2018-2023)
Figure 31. Global Cancer Companion Diagnostic Market Share Forecast by Application (2024-2029)
Figure 32. North America Cancer Companion Diagnostic Consumption Value Market Share by Type (2018-2029)
Figure 33. North America Cancer Companion Diagnostic Consumption Value Market Share by Application (2018-2029)
Figure 34. North America Cancer Companion Diagnostic Consumption Value Market Share by Country (2018-2029)
Figure 35. United States Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 36. Canada Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 37. Mexico Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 38. Europe Cancer Companion Diagnostic Consumption Value Market Share by Type (2018-2029)
Figure 39. Europe Cancer Companion Diagnostic Consumption Value Market Share by Application (2018-2029)
Figure 40. Europe Cancer Companion Diagnostic Consumption Value Market Share by Country (2018-2029)
Figure 41. Germany Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 42. France Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 43. United Kingdom Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 44. Russia Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 45. Italy Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 46. Asia-Pacific Cancer Companion Diagnostic Consumption Value Market Share by Type (2018-2029)
Figure 47. Asia-Pacific Cancer Companion Diagnostic Consumption Value Market Share by Application (2018-2029)
Figure 48. Asia-Pacific Cancer Companion Diagnostic Consumption Value Market Share by Region (2018-2029)
Figure 49. China Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 50. Japan Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 51. South Korea Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 52. India Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 53. Southeast Asia Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 54. Australia Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 55. South America Cancer Companion Diagnostic Consumption Value Market Share by Type (2018-2029)
Figure 56. South America Cancer Companion Diagnostic Consumption Value Market Share by Application (2018-2029)
Figure 57. South America Cancer Companion Diagnostic Consumption Value Market Share by Country (2018-2029)
Figure 58. Brazil Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 59. Argentina Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 60. Middle East and Africa Cancer Companion Diagnostic Consumption Value Market Share by Type (2018-2029)
Figure 61. Middle East and Africa Cancer Companion Diagnostic Consumption Value Market Share by Application (2018-2029)
Figure 62. Middle East and Africa Cancer Companion Diagnostic Consumption Value Market Share by Country (2018-2029)
Figure 63. Turkey Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 64. Saudi Arabia Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 65. UAE Cancer Companion Diagnostic Consumption Value (2018-2029) & (USD Million)
Figure 66. Cancer Companion Diagnostic Market Drivers
Figure 67. Cancer Companion Diagnostic Market Restraints
Figure 68. Cancer Companion Diagnostic Market Trends
Figure 69. Porters Five Forces Analysis
Figure 70. Manufacturing Cost Structure Analysis of Cancer Companion Diagnostic in 2022
Figure 71. Manufacturing Process Analysis of Cancer Companion Diagnostic
Figure 72. Cancer Companion Diagnostic Industrial Chain
Figure 73. Methodology
Figure 74. Research Process and Data Source
